Clinical Trials Directory

Trials / Unknown

UnknownNCT04890457

Brain, Behavior and Endocrine Effects of Transcutaneous Vagus Nerve Stimulation

Transcutaneous Vagus Nerve Stimulation Promotes Oxytocin Release and Increases Fixations on Nose

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
54 (estimated)
Sponsor
University of Electronic Science and Technology of China · Academic / Other
Sex
All
Age
18 Years – 28 Years
Healthy volunteers
Accepted

Summary

The main aim of the study is to investigate whether the transcutaneous vagus nerve stimulation(tVNS) promotes oxytocin release and the potential biomarkers of tVNS based on eye-tracking data

Detailed description

A randomized, single-blinded, sham-controlled, within-subject, crossover design will be employed in this study. In a randomized order, a total of 54 healthy subjects will receive transcutaneous vagus nerve stimulation via tragus and sham stimulation vis earlobe in the left ear (interval between these two stimulations will be 1 week). Eye-tracking and behavioral data will be collected before and after 30 minutes of stimulation, saliva samples will be collected before and after 30 minutes of stimulation, and the end of the experiment. Some personal traits will be assessed using different kinds of questionnaires, such as the Autism Spectrum Quotient(ASQ), Social Responsiveness Scale(SRS), State-Trait Anxiety Inventory (STAI), Beck's Depression Inventory(BDI), and Toronto Alexithymia Scale (TAS-20).

Conditions

Interventions

TypeNameDescription
DEVICEVagus nerve stimulation via tragusThe device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
DEVICESham stimulation via earlobeThe device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.

Timeline

Start date
2021-03-05
Primary completion
2021-06-15
Completion
2021-12-30
First posted
2021-05-18
Last updated
2021-06-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04890457. Inclusion in this directory is not an endorsement.